Evidence map›Paper›PMID 37703265›Full record

ArticlePloS one2023

Brain-derived neurotrophic factor genetic polymorphism rs6265 and creativity.

Elisabeth Hertenstein, Marion Kuhn, Nina Landmann, Jonathan-Gabriel Maier, Carlotta Louisa Schneider, Kristoffer Daniel Fehér, Lukas Frase, Dieter Riemann, Bernd Feige, Christoph Nissen

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elisabeth HertensteinFaculty of Medicine, Department of Psychiatry, University of Geneva, Geneva, Switzerland.ORCID 0000-0001-6467-0933
Marion KuhnFaculty of Medicine, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.
Nina LandmannFaculty of Medicine, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.
Jonathan-Gabriel MaierUniversity Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Carlotta Louisa SchneiderUniversity Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Kristoffer Daniel FehérFaculty of Medicine, Department of Psychiatry, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-1205-7157
Lukas FraseFaculty of Medicine, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-0841-3630
Dieter RiemannFaculty of Medicine, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.
Bernd FeigeFaculty of Medicine, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.
Christoph NissenFaculty of Medicine, Department of Psychiatry, University of Geneva, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein brain-derived neurotrophic factor (BDNF) promotes neural plasticity of the central nervous system and plays an important role for learning and memory. A single nucleotide polymorphism (rs6265) at position 66 in the pro-region of the human BDNF gene, resulting in a substitution of the amino acid valine (val) with methionine (met), leads to attenuated BDNF secretion and has been associated with reduced neurocognitive function. Inhomogeneous results have been found regarding the effect of the BDNF genotype on behavior. We determined the BDNF genotype and performance on the Compound Remote Associate (CRA) task as a common measure of creativity in 76 healthy university students. In our main analyses, we did not find significant differences between met-carriers (n = 30) and non-met carriers (n = 46). In a secondary analysis, we found that met-carriers had a slower solution time (medium effect size) for items of medium difficulty. Our results suggest that met-carriers and non-met-carriers do not generally differ regarding their creativity, but non-met-carriers may have a certain advantage when it comes to moderately difficult problems. The wider literature suggests that both genetic variants come with advantages and disadvantages. Future research needs to sharpen our understanding of the disadvantages and, potentially, advantages met allele carriers may have.

Indexed as

Brain-Derived Neurotrophic FactorMethionineGenotypeHumansPolymorphism, Single NucleotideRacemethionineBDNF protein, humanBrain-Derived Neurotrophic FactorMethionineRacemethionine

Identifiers

PMID37703265
PMCPMC10499242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.